DS-2243a (NY-ESO-1 Targeted T Cell Engager Therapy) In AdvancedSynovial Sarcoma And Solid Tumors
Trial ID: NCT06644755
Phase: Phase 1
Status: Recruiting
Last Update Posted: July 2025
Eligibility: Adults aged 18 and older with advanced or metastatic synovial sarcoma who are HLA-A*02 positive, have measurable disease, and have relapsed from, are refractory to, or cannot tolerate standard therapies.
Overview: This first-in-human Phase 1 trial evaluates DS-2243a, an investigational immunotherapy that engages the body’s T-cells to attack tumor cells expressing the NY-ESO-1 protein. The trial includes a dose-escalation phase to establish a safe dose, followed by a dose-expansion phase with a dedicated synovial sarcoma and myxoid/round cell liposarcoma cohort.
Preliminary Effectiveness: As an early Phase 1 trial, the primary goals are safety and optimal dosing. No results have been posted to ClinicalTrials.gov at this time.

Study Contact: Daiichi Sankyo

Treatment Centers: USA, Belgium, France, Netherlands, South Korea